{"id":32485,"date":"2012-10-24T19:07:43","date_gmt":"2012-10-24T23:07:43","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=32485"},"modified":"2012-10-24T19:07:43","modified_gmt":"2012-10-24T23:07:43","slug":"tct-impressive-survival-benefit-for-tavr-in-inoperable-patients-at-3-years","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/10\/24\/tct-impressive-survival-benefit-for-tavr-in-inoperable-patients-at-3-years\/","title":{"rendered":"TCT: Impressive Survival Benefit for TAVR in Inoperable Patients at 3 Years"},"content":{"rendered":"<p>At the TCT meeting in Miami, Murat Tuzcu presented the latest findings from the PARTNER B trial comparing transcatheter aortic valve replacement (TAVR) with standard therapy in patients who are not considered eligible for surgical valve replacement. At 3 years, the mortality advantage continued to grow for TAVR over standard therapy.<\/p>\n<p>All-cause mortality at 3 years:<\/p>\n<ul>\n<li>80.9% in the control group versus 54.1% in the TAVR group (HR 0.53, CI 0.41-0.68, p&lt;0.0001)<\/li>\n<\/ul>\n<p>The difference between the groups has increased from an absolute difference of 20.1% at 1 year (50.8% vs. 30.7%), to 25% at 2 years (68% vs. 43%), to 26.8% at 3 years. Here are the other endpoints reported by Tuzcu:<\/p>\n<p>Rehospitalization at 3 years:<\/p>\n<ul>\n<li>75.7% versus 42.3% (HR 0.39, CI 0.28-0.54, p&lt;0.0001)<\/li>\n<\/ul>\n<p>Mortality or rehospitalization at 3 years:<\/p>\n<ul>\n<li>93.1% versus 66.3% (HR 0.46, CI 0.36-0.58)<\/li>\n<\/ul>\n<p>Mortality or stroke at 3 years:<\/p>\n<ul>\n<li>80.9% versus 57.5% (HR 0.60, CI 0.46-0.77, p&lt;0.0001)<\/li>\n<\/ul>\n<p>The 3-year results, concluded Tuzcu, &#8220;continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates.&#8221; In addition, the results &#8220;underscore the importance of patient selection before TAVR and the need for aggressive management of illnesses after TAVR.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the TCT meeting in Miami, Murat Tuzcu presented the latest findings from the PARTNER B trial comparing transcatheter aortic valve replacement (TAVR) with standard therapy in patients who are not considered eligible for surgical valve replacement. At 3 years, the mortality advantage continued to grow for TAVR over standard therapy. All-cause mortality at 3 [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,9],"tags":[424,912,423,770],"class_list":["post-32485","post","type-post","status-publish","format-standard","hentry","category-cardiac-surgery","category-interventional-cardiology","tag-aortic-valve-replacement","tag-sapien","tag-tavi","tag-tavr"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/32485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=32485"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/32485\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=32485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=32485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=32485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}